LifeMD (LFMD) Set to Announce Earnings on Monday

LifeMD (NASDAQ:LFMD) is anticipated to post its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect LifeMD to announce earnings of ($0.14) per share and revenue of $48.80 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). LifeMD had a net margin of 0.10% and a negative return on equity of 168.23%. The business had revenue of $47.28 million for the quarter, compared to the consensus estimate of $49.16 million. On average, analysts expect LifeMD to post ($0.48) EPS for the current fiscal year and ($0.06) EPS for the next fiscal year.

LifeMD Trading Up 1.4%

NASDAQ LFMD traded up $0.03 during trading on Monday, hitting $2.32. The company had a trading volume of 24,761 shares, compared to its average volume of 995,807. The company’s fifty day moving average is $2.81 and its 200-day moving average is $3.65. LifeMD has a one year low of $2.06 and a one year high of $5.96. The company has a market cap of $111.97 million, a price-to-earnings ratio of -46.09 and a beta of 2.19.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on LFMD shares. Mizuho set a $7.00 price target on LifeMD in a research report on Thursday, August 6th. Lake Street Capital set a $5.00 price target on shares of LifeMD in a report on Thursday, August 6th. BTIG Research lowered their price objective on shares of LifeMD from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of LifeMD in a research note on Thursday, September 17th. Finally, Wall Street Zen lowered LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, LifeMD presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.57.

About LifeMD

LifeMD, Inc is a direct-to-consumer telehealth company that provides virtual medical care, prescription treatments and related health services through its digital platform. The company connects patients with licensed health care providers for online consultations, ongoing care and, when clinically appropriate, prescription medications.

Its services include virtual primary care and programs focused on areas such as weight management, men’s health, women’s health, dermatology and chronic-care support.